Decoy Therapeutics Inc.
DCOY· Nasdaq
DCOYDecoy Therapeutics Inc.
Filed Mar 23, 2020 · 10-K · 83 days after period end · 0001615219-20-000014
derived · Computed from the longer spans the company filed.
| Metric | Q4 2019dderived from reported figures | Q4 2018 | Q4 2017 | Q4 2016 |
|---|---|---|---|---|
| Revenue | $1.04M | $163.07K | $282.83K | $298.90K |
| Net Income | -$1.88M | -$2.01M | -$8.03M | -$7.90M |
| EPS Diluted | — | -$0.11 | -$0.46 | -$0.48 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
ended Dec 31, 2019 · filed Mar 23, 2020 · 83 d after period end
